ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bemnifosbuvir

Also written as “AT-527”, “Bemnifosbuvir (BEM)” and “AT-527 + digoxin”.

Its studies are mostly in Hepatitis C, Chronic · COVID-19 · Renal Insufficiency, led by 2 companies.

Drug pageBemnifosbuvir: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 26, 202226 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Atea Pharmaceuticals240 open or runningphase 3since Nov 26, 2022Jul 13, 2017none ahead
Hoffmann-La Rocheits history only20 open or runningphase 3since May 10, 2021Jan 12, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Atea Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Jul 13, 2017.

  1. Jul 28, 2021Named bemnifosbuvirINNProposed as its International Nonproprietary Name in WHO's List 125 · before, AT-527
  2. Oct 28, 2021Phase 1 study in Healthy Volunteers StudyNCT05137626 · 29 enrolled · Canada
  3. Nov 16, 2021Phase 1 study in Healthy Volunteer StudyNCT05154123 · 29 enrolled · Canada
  4. Feb 16, 2022Phase 1 study in Healthy Volunteer StudyNCT05256732 · 136 enrolled · Canada
  5. Oct 26, 2022Phase 1 study in Renal InsufficiencyNCT05618314 · 36 enrolled · Canada
  6. Nov 26, 2022Phase 3 study in COVID-19NCT05629962 · 2,285 enrolled · United States, Argentina, Brazil and more
  7. Jan 24, 2023Phase 1 study in Healthy VolunteerNCT05724693 · 39 enrolled · United States
  8. Feb 9, 2023Phase 1 study in Healthy Volunteer StudyNCT05731843 · 32 enrolled · Canada
  9. Apr 20, 20232 phase 1 studies in Healthy Volunteer StudyNCT05905497, NCT05905484
  10. Jun 6, 2023Phase 2 study in Hepatitis C, ChronicNCT05904470 · 275 enrolled · United States, Brazil, Canada and more
  11. Jan 2, 2024Phase 1 study in Healthy Volunteer StudyNCT06204679 · 42 enrolled · United States
  12. Mar 24, 2025Phase 1 study in Renal InsufficiencyNCT06911320 · 28 enrolled · United States
  13. May 19, 2025Phase 1 study in Healthy Volunteer StudyNCT07007806 · 20 enrolled · United States
  14. Nov 19, 2025Phase 1 study in Healthy Volunteer StudyNCT07272889 · 24 enrolled · Canada
  15. Dec 18, 2025Phase 1 study in Healthy Volunteer StudyNCT07314346 · 30 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 24 Atea Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07314346Healthy Volunteer Study · United States1CompletedJul 23, 202630
NCT07272889Healthy Volunteer Study · Canada1CompletedFeb 17, 202624
NCT07007806Healthy Volunteer Study · United States1CompletedJun 28, 202520
NCT06911320Renal Insufficiency · United States1CompletedApr 30, 202628
NCT06204679Healthy Volunteer Study · United States1CompletedAug 25, 202442
NCT05904470Hepatitis C, Chronic · United States, Brazil, Canada and more2CompletedDec 9, 2024275
NCT05905497Healthy Volunteer Study · United States1CompletedMay 19, 202314
NCT05905484Healthy Volunteer Study · Canada1CompletedMay 31, 202335
NCT05731843Healthy Volunteer Study · Canada1CompletedMar 15, 202332
NCT05724693Healthy Volunteer · United States1CompletedApr 23, 202439
NCT05629962COVID-19 · United States, Argentina, Brazil and more3CompletedApr 25, 20242,285
NCT05618314Renal Insufficiency · Canada1CompletedJun 15, 202436
NCT05256732Healthy Volunteer Study · Canada1CompletedAug 23, 2022136
NCT05154123Healthy Volunteer Study · Canada1CompletedDec 23, 202129
NCT05137626Healthy Volunteers Study · Canada1CompletedDec 12, 202129
NCT05004415Healthy Volunteer Study · United States1CompletedAug 12, 20216
NCT04877769Healthy Volunteer Study · United Kingdom1CompletedAug 31, 202124
NCT04865445Healthy Volunteer Study · Canada1CompletedMay 15, 202124
NCT04784000Healthy Volunteer Study · Canada1CompletedApr 10, 202120
NCT04711187Healthy Volunteer Study · Canada1CompletedSep 15, 202181
NCT04396106COVID-19 · United States, Argentina, Belgium and more2TerminatedJan 10, 202283
NCT04309734Hepatitis C · Belgium2WithdrawnJun 20220
NCT04019717Hepatitis C · Belgium, Mauritius, Moldova, Republic of2CompletedJan 29, 202010
NCT03219957Hepatitis C, Chronic · Belgium, Moldova, Republic of1CompletedJun 20, 201888

How it is read

Names in the registry

  • “AT-527”, 10 entries
  • “Bemnifosbuvir (BEM)”, 4 entries
  • “AT-527 + digoxin”, 2 entries
  • “AT-527 550 mg + midazolam”, 2 entries
  • “Buprenorphine/Naloxone + BEM/RZR”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.